|
2.4 Etiologie - Portables, ondes e-m
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
Merck Teams With Moderna To Take On One Of The Toughest Targets In Cancer [Forbes]
|
|
|
|
|
|
The
two companies have collaborated since 2016 on a personalized vaccine to
treat cancer that has to be made individually for each patient. This
will be different: an off-the-shelf vaccine that would be given to
patients whose tumors test positive for a gene called KRAS. Drug
companies have tried, repeatedly, to develop KRAS drugs. They have
failed.
|
|
|
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
Merck Provides Update on KEYNOTE-407 Trial [Merck]
|
|
|
|
|
|
The
pivotal Phase 3 KEYNOTE-407 trial investigating KEYTRUDA®
(pembrolizumab), Merck’s anti-PD-1 therapy, in combination with
carboplatin-paclitaxel or nab-paclitaxel as first line treatment for
metastatic squamous non-small cell lung cancer (sNSCLC) met a
pre-specified secondary endpoint of overall response rate (ORR) in an
early cohort of participants at an interim analysis.
|
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.1 Observation
|
|
|
|
6.11 Patients
|
|
|
|
6.6 Publications
|
|
|